BMS Archive

Fungi · Scientific monograph

Ophiocordyceps sinensis

Wild Tibetan Caterpillar Fungus

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Stress Response Research, Renal Mechanisms, Immunological Research

Research overview

Historical use

The taxonomically correct name for the wild-harvested Tibetan caterpillar fungus, previously classified as Cordyceps sinensis. Formed from parasitism of Hepialus moth larvae at altitudes >3,500 m on the Tibetan Plateau. Documented in Tibetan medical texts since the 15th century as a potent tonic for fatigue, sexual vitality, respiratory capacity, and kidney function. Among the most expensive natural substances per gram globally.

Modern research context

Clinically validated in Chinese RCTs for chronic kidney disease — combined use with ACE inhibitors or ARBs has demonstrated reductions in proteinuria and creatinine stabilisation in diabetic nephropathy [1][2] and general CKD [3]. Systematic review data support inclusion in integrative oncology discussions, though evidence quality varies [4]. Because wild harvesting is unsustainable and prohibitively expensive, nearly all modern research uses cultured Cs-4 mycelium (often still labelled 'Cordyceps sinensis') [5]. Anti-fatigue and VO2-max improvement in elderly subjects have been documented with cultured preparations [5].

Adverse effects

Mild GI upset. Rare hypersensitivity. Potential hypoglycaemia with antidiabetic co-administration. Bleeding risk with anticoagulants.

Contraindications

Anticoagulants. Immunosuppressants (cyclosporine). Autoimmune conditions — caution. Pre-surgery.

Clinical and phytochemical data

Used part

Whole fruiting body-larvae complex (wild); Cs-4 mycelium (cultured, commercially used)

Primary active compounds

  • Cordycepin (3'-deoxyadenosine)

  • Adenosine

  • D-Mannitol

  • Polysaccharides (CSPS)

  • Cyclosporin-related peptides (cyclosporins J, K)

  • Beta-glucans

Mechanism of action

Cordycepin inhibits mRNA polyadenylation, blocking cancer cell proliferation. Adenosine receptor modulation regulates cardiac output and vascular tone. HIF-1α stabilisation improves tissue oxygenation under hypoxic conditions. Cordycepin activates AMPK, enhancing glucose uptake in muscle. Th1/Th2 balance regulation via IL-12/IL-10 axis modulation.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — D-Mannitol, a naturally occurring sugar alcohol enriched in Ophiocordyceps sinensis, is absorbed after oral ingestion in humans; plasma PK was characterised in a multicentre clinical study using doses of 50–150 g (pharmacological laxative doses, substantially higher than dietary amounts from mushroom sources) [1]. No human oral absorption data exist for cordycepin, adenosine, or polysaccharide fractions at nutritional doses. Same profile as cultured Cordyceps — cordycepin rapidly deaminated. Unique wild-type peptides: oral bioavailability likely very low due to GI degradation.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cordycepin distributes rapidly to lung, kidney, liver, and immune tissues. CSE-PS (polysaccharide) concentrates in spleen and thymus. Adenosine has a very short plasma half-life (~10 seconds) due to active cellular uptake. Plasma protein binding of nucleoside compounds is generally low (<30%). Pharmacokinetics closely parallel those of Cordyceps sinensis (Cs-4).

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Metabolic pathway data for cordycepin (primary bioactive compound) available in Lee JB et al. (2019), Sci Rep [2]: cordycepin is rapidly deaminated to 3'-deoxyinosine by adenosine deaminase; a novel nucleoside rescue pathway enables oral bioactivity despite this rapid first-pass degradation. Hepatic metabolism; adenosine deaminase-mediated for cordycepin.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Renal excretion of purine metabolites.

Safety and interactions

Drug interactions

Cyclosporine (the immunosuppressant) — potential pharmacodynamic interaction as the fungus contains cyclosporin analogues. Anticoagulants, antidiabetics — same as Cordyceps sinensis.

Toxicity

Wild form: same general profile as Cs-4. Heavy metal contamination has been documented in some wild specimens from polluted regions — an important quality concern. Cs-4 cultured mycelium has a characterised tolerability profile from clinical studies; the wild form has limited controlled safety data and additional quality concerns regarding contamination.

Special precautions

Pregnancy

Insufficient data. Avoid during pregnancy.

Lactation

Insufficient data. Avoid during breastfeeding.

Hepatic impairment

No hepatotoxicity documented. Standard monitoring recommended.

Renal impairment

Studied as renoprotective agent in CKD. Monitor renal function during use. Caution with severe impairment.

Sources and references

  1. [1] - Yan G., "The effects of Ophiocordyceps sinensis combined with ACEI/ARB on diabetic kidney disease: A systematic review and meta-analysis.", Phytomedicine, 2023, PMID: 36375237
  2. [2] - Xue X., "Ophiocordyceps sinensis preparations combined with the renin-angiotensin system inhibitor in treating diabetic nephropathy.", Front Pharmacol, 2024, PMID: 38716236
  3. [3] - Luo Y., "Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitor therapy for treatment of IgA nephropathy.", Ren Fail, 2015, PMID: 25682973
  4. [4] - Narayanan S., "Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies.", Curr Oncol Rep, 2023, PMID: 36995535
  5. [5] - Łysakowska P., "Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review.", Molecules, 2023, PMID: 37513265

Additional source links

Continue browsing